Skip to content

U-100 unit conversion

SS-31 calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

5U-100 units · 0.05 mL

50 mcg per unit · 5000 mcg/mL

How the calculator works, sources and review dates

SS-31 math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 10 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-15. source-curated; clinician review pending.

Units chart for listed SS-31 sizes

U-100 math for listed SS-31 sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
10 mg1005033.3

What is SS-31?

Other names in the library: elamipretide, forzinity, SS-31 (10MG). The cited evidence and any approval concern the studied or labeled preparation. Oral, nasal, cosmetic and research-market versions do not inherit product approval or proven efficacy. Listed sizes: 10 mg. A seller title is a listing. It does not prove the vial matches a paper.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Regulatory context

Primary evidence or regulator source

Barth syndrome patients meeting the approved Forzinity criteria; accelerated approval uses a surrogate endpoint.

Reported findings. FDA describes improved knee-extension muscle strength as the surrogate basis for accelerated Forzinity approval in eligible Barth syndrome patients; patient-function benefit requires confirmation.

Nonresponse. A post-approval randomized, double-blind, placebo-controlled trial is required to confirm whether muscle-strength changes translate into patient benefit. The announcement supplies no general response rate.

Harms. The announcement reports mild-to-moderate injection-site reactions as most common, and also serious reactions without quantifying their frequency or subtype.

Limits. Labeled preparation only; marketed variants do not inherit approval. Regulatory approval and evidence of clinical benefit are separate dimensions. The announcement does not establish effects in healthy people, other indications or research preparations.

Preparation: Forzinity (elamipretide) has accelerated FDA approval for Barth syndrome in patients weighing at least 30 kg. This does not approve other uses or research products. Route: subcutaneous Forzinity

Read original source ↗

Editorial review 2026-10-15. Clinician review pending.

Human trial

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

218 people with genetically confirmed primary mitochondrial myopathy; 24-week randomized comparison.

Reported findings. The study tested walking distance and fatigue; no significant benefit over placebo was established.

Nonresponse. Neither primary walking-distance nor fatigue outcome improved significantly versus placebo.

Harms. Adverse events in 107/109 versus 83/109; predominantly injection-site reactions. Discontinuations due to adverse events: 8/109 versus 2/109.

Limits. Disease-specific controlled trial does not establish energy benefits in healthy users or safety of commercial research vials.

Preparation: Controlled elamipretide preparation; research-vial equivalence unverified. Route: subcutaneous

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human trial

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.

12 participants with genetically confirmed Barth syndrome; blinded crossover.

Reported findings. The controlled phase tested walking distance and symptom scores.

Nonresponse. Both primary outcomes were not significantly improved in the controlled phase.

Harms. Frequent injection-site reactions reported.

Limits. Small rare-disease crossover study; uncontrolled extension results are a separate evidence stream.

Preparation: Controlled elamipretide preparation; research-vial equivalence unverified. Route: subcutaneous

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Clinical observation

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.

Same TAZPOWER cohort; eight reached open-extension week 36.

Reported findings. Walking distance and symptom scores improved from baseline among extension participants.

Nonresponse. Controlled primary outcomes were null; extension has no concurrent placebo comparison.

Harms. Injection-site reactions common.

Limits. Selected extension completers; improvement from baseline is not causal proof. Later follow-up is the same cohort.

Preparation: Controlled elamipretide preparation; research-vial equivalence unverified. Route: subcutaneous

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Clinical observation

Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.

Same TAZPOWER cohort; ten entered extension, eight reached week 168.

Reported findings. Walking, fatigue and cardiac-measure improvements reported from extension baseline.

Nonresponse. No concurrent placebo control; nonresponse beyond retained participants is not established.

Harms. Injection-site reactions were the most common adverse events.

Limits. Follow-up of the same cohort, not independent replication. Attrition and open treatment limit interpretation.

Preparation: Controlled elamipretide preparation; research-vial equivalence unverified. Route: subcutaneous

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

approved product. Forzinity (elamipretide) has accelerated FDA approval for Barth syndrome in patients weighing at least 30 kg. This does not approve other uses or research products.

Compounding

not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.

Research

product specific. Barth syndrome patients meeting the approved Forzinity criteria; accelerated approval uses a surrogate endpoint.

Sport

unknown. Not individually verified; consult your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human value is generalized here to research-labeled SS-31 products.

Half-life on file: no single hour value. No verified human value is generalized here to research-labeled SS-31 products. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

Risks and mix-ups already on the record

  • Injection-site reactions were the most common adverse reactions reported with the approved Forzinity product.
  • The approved product label warns about hypersensitivity; approval does not establish the safety or quality of research-market preparations.
  • Unknown or incomplete for research formulations; this is not a clearance for use.
  • Unknown or incomplete; do not infer compatibility with medications or other substances.

People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.

Sources

  1. Primary evidence or regulator source · checked 2026-10-09

Questions people ask

Is SS-31 FDA-approved?

approved product. Forzinity (elamipretide) has accelerated FDA approval for Barth syndrome in patients weighing at least 30 kg. This does not approve other uses or research products.

Does PepBear pick an amount of SS-31?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

How many units is a listed SS-31 vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.